NO20060155L - Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer - Google Patents

Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer

Info

Publication number
NO20060155L
NO20060155L NO20060155A NO20060155A NO20060155L NO 20060155 L NO20060155 L NO 20060155L NO 20060155 A NO20060155 A NO 20060155A NO 20060155 A NO20060155 A NO 20060155A NO 20060155 L NO20060155 L NO 20060155L
Authority
NO
Norway
Prior art keywords
preparation
indole
modulators
sulfonamide derivatives
stereoisomers
Prior art date
Application number
NO20060155A
Other languages
English (en)
Inventor
Ramon Merce Vidal
Alberto Dordal Zueras
Xavier Codony Soler
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of NO20060155L publication Critical patent/NO20060155L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Foreliggende oppfinnelse angår nye sulonamidderivater med den generelle formel (la, lb, le), eventuelt i form av en av deres stereoisomerer, fortrukket enantiomerer eller diastereomerer, deres racemater, eller i form av en blanding av minst to av deres stereoisomerer, i et hvilket som helst blandingsforhold, eller saltene derav, fortrinnsvis de tilsvarende fysiologisk akseptable saltene derav, eller tilsvarende solvater derav, fremgangsmåter for deres fremstilling, anvendelsen av dem som medikamenter i human- og/eller veterinærterapeutika, og de farmasøytiske sammensetningene inneholdende dem.
NO20060155A 2003-07-30 2006-01-10 Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer NO20060155L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301807A ES2222829B1 (es) 2003-07-30 2003-07-30 Derivados de 4-indolilsulfonamidas, su preparacion y su aplicacion como medicamentos.
PCT/EP2004/008512 WO2005013978A1 (en) 2003-07-30 2004-07-29 Indol-4 sulfonamide derivatives, their preparation and their use 5-ht-6 as modulators

Publications (1)

Publication Number Publication Date
NO20060155L true NO20060155L (no) 2006-01-10

Family

ID=34130541

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060155A NO20060155L (no) 2003-07-30 2006-01-10 Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer

Country Status (22)

Country Link
US (1) US8097643B2 (no)
EP (1) EP1648446B1 (no)
JP (1) JP2007500166A (no)
KR (1) KR20060123698A (no)
CN (1) CN100518736C (no)
AT (1) ATE432700T1 (no)
AU (1) AU2004262486A1 (no)
BR (1) BRPI0413068A (no)
CA (1) CA2534098A1 (no)
DE (1) DE602004021385D1 (no)
EC (2) ECSP066322A (no)
ES (2) ES2222829B1 (no)
IL (1) IL172892A0 (no)
MX (1) MXPA06001137A (no)
NO (1) NO20060155L (no)
NZ (1) NZ545300A (no)
PE (1) PE20050333A1 (no)
PT (1) PT1648446E (no)
RU (1) RU2006105778A (no)
TW (1) TW200505855A (no)
WO (1) WO2005013978A1 (no)
ZA (1) ZA200600421B (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007373A4 (en) * 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007012284A1 (de) * 2007-03-16 2008-09-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
EP2018861A1 (en) * 2007-07-26 2009-01-28 Laboratorios del Dr. Esteve S.A. 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain
DE102007035334A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
ATE495737T1 (de) 2007-08-01 2011-02-15 Esteve Labor Dr Kombination von mindestens zwei 5-ht6-liganden
DE102007042154A1 (de) 2007-09-05 2009-03-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Arylsulfonylaminomethyphosphonsäure-Derivate, deren Herstellung und deren Verwendung als Arzneimittel
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
PL2300489T3 (pl) 2008-06-06 2016-11-30 Sposoby wytwarzania 17-alkinylo-7-hydroksysteroidów i związków pokrewnych
US20190336585A1 (en) * 2018-05-03 2019-11-07 John Lawrence Mee Method for sustainable human cognitive enhancement
US20190390193A1 (en) * 2018-06-23 2019-12-26 John Lawrence Mee Reversible method for sustainable human cognitive enhancement

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472870A (en) * 1966-08-29 1969-10-14 Mead Johnson & Co Sulfonamidotryptamines
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
AU702322B2 (en) 1995-03-20 1999-02-18 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
US5939451A (en) * 1996-06-28 1999-08-17 Hoffmann-La Roche Inc. Use of sulfonamides
GB9902459D0 (en) * 1999-02-05 1999-03-24 Zeneca Ltd Chemical compounds
US6043706A (en) * 1999-02-05 2000-03-28 Ericsson Inc. Methods and apparatus for controlling power amplifier quiescent current in a wireless communication device
US6521658B1 (en) * 1999-05-28 2003-02-18 Abbott Laboratories Cell proliferation inhibitors
GB9926302D0 (en) 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
MXPA03006605A (es) * 2001-01-30 2003-09-22 Lilly Co Eli Esteres de indol-5-ilo del acido bencensulfonico como antagonistas del receptor 5-ht6.
ES2187300B1 (es) 2001-11-14 2004-06-16 Laboratorios Del Dr. Esteve, S.A. Derivados de sulfonamidas, su preparacion y su aplicacion como medicamentos.
ES2313002T3 (es) * 2003-05-09 2009-03-01 Laboratorios Del Dr. Esteve, S.A. Uso de derivados de sulfonamida para la fabricacion de un medicamento para la profilaxis y/o tratamiento de la ingestion de alimentos.

Also Published As

Publication number Publication date
WO2005013978A1 (en) 2005-02-17
JP2007500166A (ja) 2007-01-11
ECSP066324A (es) 2006-08-30
ES2327848T3 (es) 2009-11-04
EP1648446B1 (en) 2009-06-03
US20070185158A1 (en) 2007-08-09
RU2006105778A (ru) 2007-09-20
US8097643B2 (en) 2012-01-17
PE20050333A1 (es) 2005-06-12
NZ545300A (en) 2008-05-30
ES2222829B1 (es) 2006-03-01
EP1648446A1 (en) 2006-04-26
ZA200600421B (en) 2007-03-28
KR20060123698A (ko) 2006-12-04
TW200505855A (en) 2005-02-16
CN1829508A (zh) 2006-09-06
CN100518736C (zh) 2009-07-29
ECSP066322A (es) 2006-08-30
BRPI0413068A (pt) 2006-10-17
PT1648446E (pt) 2009-09-03
IL172892A0 (en) 2006-06-11
AU2004262486A1 (en) 2005-02-17
ATE432700T1 (de) 2009-06-15
DE602004021385D1 (de) 2009-07-16
MXPA06001137A (es) 2006-04-24
ES2222829A1 (es) 2005-02-01
CA2534098A1 (en) 2005-02-17

Similar Documents

Publication Publication Date Title
NO20060682L (no) Indol-6 sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer
NO20060342L (no) 1-sulfonylindol derivater, deres fremstilling og deres andvendelse som 5-HT6 ligander
NO20060865L (no) Indol-5-YL sulfonamid derivater, deres fremstilling og deres anvedelse 5-HT-6 som modulatorer
NO20085078L (no) Nye forbindelser
ES2158814B1 (es) Derivados de pirrolidina antagonistas del receptor ccr-3
NO20080670L (no) Substituerte piperaziner som metabotrofiske glutamatreseptorantagonister
NO20063470L (no) Tetrazolforbindelser og deres anvendelse av metabotrofe glutamatreseptorantagonister
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20050828L (no) lndol-3-svovelderivater
NO20050134L (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
NO20045486L (no) Nye forbindelser og deres anvendelse
SE0302192D0 (sv) Novel compounds
EA200601194A1 (ru) Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
SG171471A1 (en) New benzimidazole derivatives
NO20091766L (no) Spiro-piperidinderivater
EA200701324A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
PT1919475E (pt) Derivados de tetrahidro-â-carbolino-sulfonamida de como ligandos de 5-ht6
TW200626553A (en) Novel compounds
NO20092149L (no) Spiro-piperidinderivater
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
TW200505855A (en) Indol-4-yl sulfonamide derivatives, their reparation and their use in medicaments
NO20062491L (no) Benzoksazinderivter og deres anvendelse
DE60208694D1 (de) Piperidinylmorpholinylderivate als modulatoren der aktivität des chemokinrezeptors
NO20055492L (no) Anvendelse av sulfonamidderivater for fremstilling av et medikament for profylakse og/eller behandling av lidelser ved matinntak

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application